

BLOCK LISTING SIX MONTHLY RETURN

May 23, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG)

Name of <i>applicant</i> :		Shire plc		
Name of scheme:		Shire Sharesave Scheme		
Period of return:	From:	November 23, 2016	To:	May 22, 2017
Balance of unallotted securities under scheme(s) from previous return:		184,611		
<i>Plus</i> : The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		Nil		
<i>Less</i> : Number of <i>securities</i> issued/allotted under scheme(s) during period (see LR3.5.7G):		17,079		
<i>Equals</i> : Balance under scheme(s) not yet issued/allotted at end of period:		167,532		

Name of <i>applicant</i> :		Shire plc		
Name of scheme:		Shire Portfolio Share Plan		
Period of return:	From:	November 23, 2016	To:	May 22, 2017
Balance of unallotted securities under scheme(s) from previous return:		769,615		
<i>Plus</i> : The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		Nil		
<i>Less</i> : Number of <i>securities</i> issued/allotted under scheme(s) during period (see LR3.5.7G):		405,083		
<i>Equals</i> : Balance under scheme(s) not yet issued/allotted at end of period:		364,532		

Name of <i>applicant</i> :		Shire plc		
Name of scheme:		Shire Employee Stock Purchase Plan		
Period of return:	From:	November 23, 2016	To:	May 22, 2017
Balance of unallotted securities under scheme(s) from previous return:		244,057		
<i>Plus</i> : The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		Nil		
<i>Less</i> : Number of <i>securities</i> issued/allotted under scheme(s) during period (see LR3.5.7G):		6,359		
<i>Equals</i> : Balance under scheme(s) not yet issued/allotted at end of period:		237,698		

Name of <i>applicant</i> :		Shire plc		
Name of scheme:		Shire Long Term Incentive Plan 2015		
Period of return:	From:	November 23, 2016	To:	May 22, 2017
Balance of unallotted securities under scheme(s) from previous return:		2,836,412		
<i>Plus</i> : The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		Nil		
<i>Less</i> : Number of <i>securities</i> issued/allotted under scheme(s) during period (see LR3.5.7G):		145,740		
<i>Equals</i> : Balance under scheme(s) not yet issued/allotted at end of period:		2,690,672		

Name of <i>applicant</i> :		Shire plc		
Name of scheme:		Shire Global Employee Stock Purchase Plan		
Period of return:	From:	November 23, 2016	To:	May 22, 2017
Balance of unallotted securities under scheme(s) from previous return:		1,604,243		
<i>Plus</i> : The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		Nil		
<i>Less</i> : Number of <i>securities</i> issued/allotted under scheme(s) during period (see LR3.5.7G):		3,400		
<i>Equals</i> : Balance under scheme(s) not yet issued/allotted at end of period:		1,600,843		

Name of <i>applicant</i> :		Shire plc		
Name of scheme:		Baxalta Exchange Awards		
Period of return:	From:	November 23, 2016	To:	May 22, 2017
Balance of unallotted securities under scheme(s) from previous return:		20,488,204		
<i>Plus</i> : The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		Nil		
<i>Less</i> : Number of <i>securities</i> issued/allotted under scheme(s) during period (see LR3.5.7G):		2,492,337		
<i>Equals</i> : Balance under scheme(s) not yet issued/allotted at end of period:		17,995,867		

Name of contact:	Sarah Rixon, Company Secretarial Assistant
Telephone number of contact:	01256 894000

For further information please contact:

Investor Relations

Ian Karp ikarp@shire.com +1 781 482 9018
Robert Coates rcoates@shire.com +44 1256 894874

Media

Lisa Adler lisa.adler@shire.com +1-617 588 8607
Debbi Ford debbi.ford@shire.com +1 617 949 9083

NOTES TO EDITORS

About Shire

Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.

Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

www.shire.com